We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-1.18%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$496M
AUM Growth
+$22M
Cap. Flow
+$34.5M
Cap. Flow %
6.96%
Top 10 Hldgs %
10.47%
Holding
461
New
27
Increased
142
Reduced
189
Closed
26

Top Buys

Rank Stock Value
1
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
+$3.17M
2
MPLX icon
MPLX
MPLX
+$3.04M
3
BLW icon
BlackRock Limited Duration Income Trust
BLW
+$2.79M
4
ABDC
Alcentra Capital Corp
ABDC
+$1.98M
5
BKCC
BlackRock Capital Investment Corporation
BKCC
+$1.92M

Top Sells

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$6.67M
2
ECC
Eagle Point Credit Company
ECC
+$5.43M
3
ANDX
Andeavor Logistics LP
ANDX
+$2.66M
4
FRA icon
BlackRock Floating Rate Income Strategies Fund
FRA
+$2.25M
5
MVC
MVC Capital, Inc.
MVC
+$1.95M

Sector Composition

Rank Sector Weight
1 Financials 24.1%
2 Real Estate 16.28%
3 Energy 14.42%
4 Healthcare 8.59%
5 Materials 8.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
201
DELISTED
Apellis Pharmaceuticals
APLS
$288K 0.06%
11,935
-665
-5% -$18.3K
MYOK
202
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$286K 0.06%
5,487
-304
-5% -$16.2K
RARX
203
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$281K 0.06%
11,881
-662
-5% -$19.6K
ARWR icon
204
Arrowhead Research
ARWR
$12.1B
$276K 0.06%
9,785
-545
-5% -$16.1K
XNCR icon
205
Xencor
XNCR
$1.44B
$272K 0.05%
8,065
-449
-5% -$17.9K
IMMU
206
DELISTED
Immunomedics Inc
IMMU
$271K 0.05%
20,448
-1,139
-5% -$16.7K
XLRN
207
DELISTED
Acceleron Pharma
XLRN
$266K 0.05%
6,721
-374
-5% -$16.2K
AIMT
208
DELISTED
Aimmune Therapeutics
AIMT
$265K 0.05%
12,634
-704
-5% -$14.4K
ONC
209
BeOne Medicines Ltd
ONC
$33.8B
$264K 0.05%
2,155
-120
-5% -$15.9K
ARVN icon
210
Arvinas
ARVN
$518M
$263K 0.05%
12,204
-680
-5% -$16.7K
TECX
211
Tectonic Therapeutic
TECX
$573M
$263K 0.05%
1,555
-86
-5% -$19.5K
MRNA icon
212
Moderna
MRNA
$21.5B
$261K 0.05%
16,397
-914
-5% -$13.5K
ALLO icon
213
Allogene Therapeutics
ALLO
$601M
$260K 0.05%
9,552
-532
-5% -$15.2K
RETA
214
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$249K 0.05%
3,101
-172
-5% -$14.6K
SGMO
215
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$246K 0.05%
27,131
-1,512
-5% -$17K
DRNA
216
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$246K 0.05%
17,115
-953
-5% -$13.6K
AGEN
217
Agenus
AGEN
$249M
$245K 0.05%
4,839
-270
-5% -$14.4K
RYTM icon
218
Rhythm Pharmaceuticals
RYTM
$7B
$244K 0.05%
11,308
-630
-5% -$13.5K
AKBA icon
219
Akebia Therapeutics
AKBA
$327M
$242K 0.05%
61,630
-3,433
-5% -$14.7K
IOVA icon
220
Iovance Biotherapeutics
IOVA
$2.23B
$241K 0.05%
13,225
-737
-5% -$16.3K
TVRD
221
Tvardi Therapeutics
TVRD
$23.5M
$238K 0.05%
362
-21
-5% -$17.5K
KYNB
222
Kyntra Bio
KYNB
$28.5M
$230K 0.05%
249
-14
-5% -$15.4K
LJPC
223
DELISTED
La Jolla Pharmaceutical Company
LJPC
$229K 0.05%
26,021
-1,449
-5% -$13.7K
TCDA
224
DELISTED
Tricida, Inc. Common Stock
TCDA
$227K 0.05%
7,354
-408
-5% -$13.7K
GBT
225
DELISTED
Global Blood Therapeutics, Inc.
GBT
$227K 0.05%
4,677
-261
-5% -$13.6K
7 8
9
10 11

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q3 2019 Portfolio in Review

As of Q3 2019, Virtus ETF Advisers held 461 positions worth $496M, up 4.6% from $474M the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Virtus ETF Advisers deployed $34.5M of net new capital in Q3 2019, opening 27 new positions and adding to 142 existing holdings. Its largest new stake was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.

By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 24% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was TriplePoint Venture Growth BDC, an estimated $813K trimmed.

  • Virtus ETF Advisers's largest Q3 2019 buy was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.
  • Virtus ETF Advisers added most to MPLX in Q3 2019, an estimated $3.04M increase.
  • Virtus ETF Advisers's biggest Q3 2019 reduction was TriplePoint Venture Growth BDC, cutting an estimated $813K.
  • Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2019, selling an estimated $6.67M.
  • Virtus ETF Advisers's ten largest holdings make up 10% of its $496M portfolio in Q3 2019.
  • Virtus ETF Advisers opened 27 new positions and closed 26 in Q3 2019.
  • Virtus ETF Advisers's portfolio value rose 4.6% quarter-over-quarter to $496M.

Based on Virtus ETF Advisers's 13F filing for Q3 2019, filed 12 Nov 2019.